×
For best experience we recommend to activate Javascript in your browser.
ADAM9 antibody (AA 440-680)
This Rabbit Polyclonal antibody specifically detects ADAM9 in WB, IHC, IP and ICC. It exhibits reactivity toward Human.
Quick Overview for ADAM9 antibody (AA 440-680) (ABIN7610239)
Target
See all ADAM9 Antibodies
ADAM9
(ADAM Metallopeptidase Domain 9 (ADAM9))
Reactivity
All reactivities for ADAM9 antibodies
Human
Host
All hosts for ADAM9 antibodies
Rabbit
Clonality
All clonalities for ADAM9 antibodies
Polyclonal
Conjugate
All conjugates for ADAM9 antibodies
This ADAM9 antibody is un-conjugated
Application
All applications for ADAM9 antibodies
Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
Product Details anti-ADAM9 Antibody
(hide)
Binding Specificity
All epitopes for ADAM9 antibodies
AA 440-680
Purpose
A Disintegrin And Metalloprotease 9 (ADAM9) Polyclonal Antibody
Sequence
Pro440~Gly680
Characteristics
The A Disintegrin And Metalloprotease 9 (ADAM9) Polyclonal Antibody (Species: Human) has been validated for the following applications: WB, IHC, ICC, IP.
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
0.5 mg/mL
Buffer
0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.
Expiry Date
12 months
Target Details for ADAM9
(hide)
Target
ADAM9
(ADAM Metallopeptidase Domain 9 (ADAM9))
Alternative Name
ADAM9
Gene ID
8754
UniProt
Q13443
Pathways
Cellular Response to Molecule of Bacterial Origin , SARS-CoV-2 Protein Interactome
Recently viewed
(hide)
Chat with us , powered by LiveChat